A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of Chidamide combined with endocrine for maintenance
therapy after first-line chemotherapy for HR+/HER2- breast cancer
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital